Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL

from Oncology Learning Network · host HMP Global

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Episode metadata supplied by the publisher feed · Published Apr 6, 2022

Embed this episode

Attribution link and audio player

Ready to play

Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL

0:00 8:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 8 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on April 6, 2022.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!